

ARV Therapies and Therapeutic Strategies

REPORTING ON IAS 2015

Comprehensive Expert Review and Discussion of Key Presentations


An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

Elvitegravir (EVG) /Cobicistat (COBI) /Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) is Superior to Ritonavir (RTV) Boosted Atazanavir (ATV) plus FTC/TDF in treatment naïve women with HIV-1 infection (WAVES Study)

K. Squires, C. Kityo, S. Hodder, D. Hagins, A. Avihingsanon, Y. Plotnikova,
E. Koenig, F. Post, S. Chen, K White, H. Cao, A. Cheng, J. Szwarcberg

Abstract MOLBPE08

WAVES Study: Design in HIV+ ART Naïve Women



Key Eligibility Criteria:


- ❖ HIV infected women
- ❖ HIV-1 RNA ≥ 500 copies/mL
- ❖ Estimated GFR ≥ 70 mL/min
- ❖ No history of prior antiretroviral therapy
- ❖ Sensitivity to FTC, TDF, and ATV
- ❖ Stratification:
 - ◆ HIV-1 RNA ($\leq 100,000$, $>100,000$ - $\leq 400,000$, $>400,000$ copies/mL)
 - ◆ Race (Black or non-Black)

WAVES Study: Baseline Characteristics of HIV+ Women

	EVG/c/FTC/TDF (n=289)	ATV/r + FTC/TDF (n=286)
Age (years), median (Q1,Q3)	34 (28,43)	35 (29,42)
Race		
White	44%	42%
Black	49%	47%
Asian	3%	6%
Mode of Infection		
Heterosexual	96%	94%
HIV Disease		
Asymptomatic	81%	75%
AIDS	4.2%	4.5%
Body Mass Index (BMI), Mean (SD)	26 (7.02)	26 (5.69)
Positive HBsAg	3.1%	2.4%
Positive HCV Antibody	7.6%	8.7%
HIV-1 RNA (log₁₀ copies/mL), Median (Q1,Q3)	4.46 (4.09,4.97)	4.56 (4.02,5.00)
< 100,000 c/mL	76%	75%
>100,000-400,000 c/mL	15%	17%
> 400,000 c/mL	9%	8%
CD4 cell count (cells/mm³), Median (Q1,Q3)	344 (246,466)	370 (244,489)
<200 cells/mm ³	17%	18%

Squires K, et al; 8th IAS, Vancouver, Canada, July 19-22, 2015; Abst. MOLBPE08.

WAVES Study: Virologic Outcomes




Mean CD4 Cell Increase (cells/mm³) was 196 (EVG/c/FTC/TDF & ATV/r + FTC/TDF)

RESISTANCE
 STB: Only on pt with emergent D67D/N
 ATV/r: 3 with M184V/I

Squires K, et al; 8th IAS, Vancouver, Canada, July 19-22, 2015; Abst. MOLBPE08.


WAVES Study: Changes in eGFR-CG* Through Week 48



*eGFR-CG = estimated Glomerular Filtration Rate by Cockcroft-Gault

Squires K, et al; 8th IAS, Vancouver, Canada, July 19-22, 2015; Abst. MOLBPE08.

WAVES Study: Changes in Spine & Hip BMD at Week 48



▲ (N) 138
■ (N) 150

120

136

128

150

118

128

No Difference in Change in TC to HDL Ratio

Squires K, et al; 8th IAS, Vancouver, Canada, July 19-22, 2015; Abst. MOLBPE08.